Nyrada Half Year Results FY2022

Highlights:
• Research and development costs of $1.13M as Nyrada’s lead preclinical programs advance (1H FY2021: $1.05M)
• Robust cash position of $11.1M as at 31 December 2021, plus R&D tax rebate of $1.3M received in January 2022, further boosting available capital resources
• Cholesterol-Lowering Program advances with preclinical studies in 1H CY2022 ahead of a Phase I first-in-human trial in Australia during 2H CY2022
• Efficacy of Nyrada’s Brain Injury Program drug candidate to be evaluated via Walter Reed & UNSW collaboration and in a well-established preclinical model of stroke
• Brain Injury Program to commence Phase I first-in-human study in 2H CY2022